| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 22 | 35.2x | 17.3x | Bottom tier | |
Growth | 9 | -68.2% | 7.1% | Bottom tier | |
Quality | 87 | 14.6% | 4.5% | Top tier | |
Safety | 59 | 3.1x | 2.6x | Around median | |
Capital Return | 23 | 0.00% | 0.06% | Bottom tier | |
Momentum | 93 | 5.0% | -1.6% | Top tier | |
Sentiment | 99 | 16 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
64% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Genmab A/S is a biotechnology company specializing in antibody science and the development of cancer therapies, with revenue based on a portfolio that includes DARZALEX, EPKINLY, and TIVDAK, alongside advanced assets such as Rina-S and petosemtamab. In the first half of fiscal year 2026, approximately half of revenue growth came from DARZALEX and the other half from EPKINLY and the rest of the portfolio, indicating a broadening of growth sources, while DARZALEX remained a key driver. Wholly owned portfolio sales reached $396 million, including $312 million from EPKINLY and $84 million from TIVDAK.
According to the latest available EDGAR filings, fiscal year 2025 quarter 2 recorded revenue of $925 million and gross profit of $868 million, equivalent to a gross margin of approximately 93.8%. Net income was $336 million, representing a net margin of approximately 36.3%, with earnings per share of 5.42. In the first half of fiscal year 2026, the company reported revenue growth of 25% and adjusted operating profit growth of 18% despite increased investment in late-stage programs, launch preparations, and the integration of Merus.
Management raised its fiscal year 2026 guidance to revenue between $4.3 and $4.5 billion, representing annual growth of 19% at the midpoint, compared with 14% in the previous guidance. It also expects operating profit between $1.1 and $1.4 billion, while the midpoint of operating expense guidance increased by only 2% to $2.88 billion. This reflects positive operating leverage, but it ties a significant portion of the company's valuation to the results of phase III studies expected in fiscal year 2026 quarter 4 and fiscal year 2027 quarter 1.
The average analyst price target is $38.25, within a range extending from $32 to $43, with a consensus Buy rating; the average is above the 52-week range high of $35.43, while the highest target exceeds that high by a wider margin. The breadth of the target range and the absence of a specified price-to-earnings multiple reflect the valuation's sensitivity to phase III results, particularly the fiscal year 2026 quarter 4 readouts, while the 52-week range extends from $23.62 to $35.43, documenting notable volatility in the repricing of expectations.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Genmab's revenue grew by 25% in the first half of fiscal year 2026, with DARZALEX increasing by 21%, EPKINLY by 48%, and the rest of the portfolio by 35%. Approximately half of the growth came from DARZALEX, while the other half came from EPKINLY and the remaining products. The company raised its fiscal year 2026 revenue guidance to a range between $4.3 and $4.5 billion.
Global EPKINLY sales reached $312 million in the first half of fiscal year 2026, up 48% annually and 28% quarterly. Sales were supported by increased treatment initiations and site activations in the United States, and more than 90% of key customers now order the drug for two or more sites. Use of the EPKINLY combination with lenalidomide and rituximab also expanded in second-line follicular lymphoma following its approval in Europe and China.
Genmab expects phase II and III results for Rina-S in platinum-resistant ovarian cancer in fiscal year 2026 quarter 4. During the same period, it expects results for petosemtamab in first-line head and neck cancer and the interim analysis of the EPCORE DLBCL-2 study. For the petosemtamab study in the second- and third-line settings for head and neck cancer, the company expects a readout in fiscal year 2027 quarter 1.
Automated analysis for informational purposes only — not investment advice.
petosemtamab is a bispecific antibody targeting EGFR and LGR5, and Genmab has initiated two global phase III studies in colorectal cancer. The first study is testing the drug with chemotherapy in the first-line setting for patients with unresectable or metastatic left-sided colorectal cancer with wild-type RAS and RAF, while the second is testing it in the second-line setting for patients with wild-type RAS. The company intends to present updated colorectal cancer data during ESMO in October 2026.
The pipeline's value depends on the success of several phase III studies, whose results were not available at the August 6, 2026 call. petosemtamab also faces competition from J&J's amivantamab in head and neck cancer and from several EGFR-targeting programs in colorectal cancer. In addition, it has not been determined with FDA whether the first-line or second-line study will serve as the confirmatory study for EPKINLY, and overall survival data from the EPCORE DLBCL-4 study were immature.
The fiscal year 2025 quarter 2 filings showed revenue of $925 million and gross profit of $868 million, equivalent to a gross margin of approximately 93.8%. Net income was $336 million, representing a net margin of approximately 36.3%, and earnings per share were 5.42. In the first half of fiscal year 2026, adjusted operating profit grew by 18%, after which the company raised its fiscal year 2026 operating profit guidance to a range between $1.1 and $1.4 billion.